AgingResearch.NewsJoin free

Travere Therapeutics

CompanyUnited States

ROR

Travere Therapeutics develops one asset, in phase 3 (sparsentan in immunoglobulin a nephropathy). Mostly small molecule acting on AGTR1 and EDNRA; based in the United States.

1
Asset
Furthest stage
Phase 3
1
Trial
1
Signal

Pipeline

1

  • sparsentan

    Blocks endothelin A and angiotensin II type 1 receptors to reduce proteinuria and protect kidney function.

    Phase 3, Small molecule, AGTR1, EDNRA, immunoglobulin a nephropathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials1
  • Signals1
  • Similar companies6

Papers

Intelligence